BOSTON, May 11 /PRNewswire/ -- The 7th Annual Anti-Cancer Drug Discovery & Development Summit will convene on July 12-13, 2005 in Boston, MA. Highly proclaimed as the premier information networking meeting in this space, this year’s meeting will bring together the finest group of oncology experts from around the world to address the most promising avenues of investigation. This summit will also consist of a partnering and licensing M&A track - aimed at business development personnel audiences, announces the Strategic Research Institute.
The opening keynote address will be delivered by Louise Grochow, Global Medical Science Director of Oncology, AstraZeneca. The talk is entitled, “The Challenges in Developing New Cancer Therapies”. Dr. Grochow, a world renowned oncologist, is also recognized as the former Chief of the Investigational Drug Branch at the National Cancer Institute.
This agenda offers the hottest and latest anti-cancer research on: 1) Targeted Therapeutics, 2) Angiogenesis, 3) Antibody Derived Targets & Biologics, and 4) New Targets. Highlighted research programs include: 2C3, PTK787, VEFR-Npn-1, OSI-930, SB-497115, VX-680, MEK Inhibitors, and Combinatorial MAb CD22/CD20 Therapies.
Complete list of participating companies and institutions includes: Actinium Pharmaceuticals, Inc., Alfacell Corporation, Amgen, Inc., AstraZeneca R&D Boston, Bayer Healthcare, Biogen Idec, Biomarker Technologies, LLC, Biovest International - An Accentia Company, Bristol Myers Squibb Company, Caprion Pharmaceuticals, Celera Genomics, Celgene Corporation, Celgene San Diego, Cell Genesys, Centocor, Inc., Decision Options, LLC, Defined Health, Genzyme Corporation, GlaxoSmithKline, Immunogen, Inc., Immunomedics, Inc., Johnson & Johnson Pharmaceutical R&D, Merck Research Laboratories, Novartis Pharmaceuticals, OSI Pharmaceuticals, Inc., Peregrine Pharmaceuticals, Pfizer Global Research & Development - Ann Arbor, Proctor & Gamble Pharmaceuticals, Rejuvenon, Sherris Pharma Partners, Veridex, LLC - A Johnson & Johnson Company, Dartmouth Medical School, Harvard Medical School Institute of Proteomics, UCLA David Geffen School of Medicine, University of Texas Southwestern Medical Center.
To receive the full agenda in PDF, please contact Ed Drilon of Strategic Research Institute at edrilon@srinstitute.com or 212-967-0095, x233 (please include name, corporate affiliation, mailing address, and fax number and specify what you are interested in).
To inquire about sponsorship & exhibition opportunities, please contact Marla Calico at mcalico@srinstitute.com.
To become a media partner, please contact Cheryl Kahan-Radhuber at ckahan-radhuber@srinstitute.com.
Strategic Research Institute
CONTACT: Ed Drilon of Strategic Research Institute,edrilon@srinstitute.com, +1-212-967-0095, x 233, or Marla Calico,mcalico@srinstitute.com, or Cheryl Kahan-Radhuber,ckahan-radhuber@srinstitute.com
Web site: http://www.srinstitute.com/
